Jinzhan Chen

Jinzhan Chen

Auto-generated profile, based on publicly available information

Jinzhan Chen

Zhongshan Hospital (Xiamen) Fudan University Xiamen China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Health Science Reports
Verified
Journal Article
Open access
JLJianying Liu
Jianying Liu
JCJinzhan Chen
Jinzhan Chen
CXCongyi Xie
Congyi Xie
HCHaiyan Chen
Haiyan Chen
SYShuwen Yang
Shuwen Yang
YXYijiao Xu
Yijiao Xu
Background and Aims: To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).Methods: We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan–Meier curves, Cox proportional hazards models, time‐dependent ROC curves, and random survival forest models.Results: The median follow‐up was 29 months (IQR: 25.96–32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression‐free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune‐related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS.Conclusion: LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.

1 October 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
JCJinzhan Chen
Jinzhan Chen
YXYijiao Xu
Yijiao Xu
JLJiaxin Liu
Jiaxin Liu
HJHongni Jiang
Hongni Jiang
NZNing Zhang
Ning Zhang
Background: Obstructive sleep apnea (OSA) is a common sleep disorder that significantly impairs sleep quality and daytime functionality, with a well-established association with obesity. To enhance the precision of OSA risk assessment, this study introduces the age-adjusted visceral adiposity index (AVAI) and investigates its association with OSA. Methods: The study utilized data from the 2015–2018 National Health and Nutrition Examination Survey (NHANES). The association of AVAI with OSA was examined through a multivariate logistic regression model. Propensity score matching (PSM) was leveraged for mitigating baseline characteristic imbalances and validating the robustness of the findings. Interaction and subgroup analyses were conducted to explore potential effect modifiers. In addition, receiver operating characteristic (ROC) curve analysis was performed to evaluate the discriminative ability of AVAI for OSA. Results: Among 3,611 participants, 1,753 were diagnosed with OSA. AVAI was significantly associated with OSA [odds ratio (OR) =1.15, 95% confidence interval (CI): 1.09, 1.21]. Participants in the highest AVAI quartile (Q4) had a notably elevated likelihood of OSA in contrast to those in the lowest quartile (Q1) (OR =2.67, 95% CI: 1.96, 3.64). This relation remained significant in the PSM-adjusted sample (OR =1.14, 95% CI: 1.09, 1.20). Subgroup analyses demonstrated that the link of AVAI to OSA was particularly significant in females, non-hypertensive individuals, non-diabetic individuals, and those without cardiovascular disease. Conclusions: This cross-sectional study establishes AVAI’s independent association with OSA. Clinically, AVAI may help identify current high-risk profiles to guide targeted management, though predictive applications require future validation.

1 March 2026 in Journal of Thoracic Disease
Verified
Journal Article
Open access
NZNing Zhang
Ning Zhang
JCJinzhan Chen
Jinzhan Chen
CXCongyi Xie
Congyi Xie
JCJinzhan Chen
Jinzhan Chen
Asthma exacerbations significantly contribute to morbidity and healthcare burden, yet accurate risk prediction remains challenging. This study aimed to develop and validate a machine learning (ML)-based model to predict the exacerbation risk in adult asthma patients. This study analyzed data from the National Health and Nutrition Examination Survey (NHANES) collected between 2007 and 2012, comprising a cohort of 1,480 adult participants diagnosed with asthma. A total of 37 candidate features were assessed, and feature selection via least absolute shrinkage and selection operator (LASSO) identified seven key predictors. Nine ML models were developed and evaluated using the area under the curve (AUC) to determine the optimal model. The best-performing model underwent further validation using calibration curves, precision-recall (PR) curves, and decision curve analysis (DCA). Shapley Additive Explanations (SHAP) was applied to interpret the model’s predictions. A light gradient boosting machine (LightGBM) model showed the best predictive performance, with an AUC of 0.902 in the training set and comparable discrimination in the validation set. Model performance in the validation cohort showed consistent results across calibration analysis, PR curves, and DCA. Model interpretability was examined using SHAP and a web-based calculator was developed to support individualized risk estimation. This ML-based model demonstrated strong predictive accuracy and could serve as a valuable tool for risk assessment of adult asthma in clinical practice.